{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:05:51Z","timestamp":1788519951936,"version":"build-2803163510"},"reference-count":10,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2008,12,31]],"date-time":"2008-12-31T00:00:00Z","timestamp":1230681600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2009,2,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In this evaluator\u2010blinded open\u2010treatment trial, subjects with moderate\/severe upper limb essential tremor were titrated to 300 mg\/day zonisamide, or adjusted to a lesser dose if symptoms warranted, as monotherapy or as adjunct to stable antitremor medication, followed by a 12\u2010week extension phase. The primary efficacy outcome variables were blinded rater videotaped\/drawing tremor score changes at the Treatment and Extension visits compared to Baseline, based on Fahn\u2010Tolosa\u2010Marin and Postural Tremor Scales. Subjects also rated Functional Disabilities. Primary outcomes showed reduced tremor scores at the Treatment (<jats:italic>P<\/jats:italic> &lt; 0.00001, n = 25) and Extension (n = 16) visits, at mean doses of 252 and 225 mg\/day, respectively. Subject ratings indicated 200 mg\/day was superior to 100 mg\/day, whereas 300 mg\/day produced no additional benefit, but instead was associated with more adverse symptoms, most commonly somnolence, poor energy, imbalance, and altered taste. Future double\u2010blind placebo\u2010controlled trials are warranted. \u00a9 2008 Movement Disorders Society<\/jats:p>","DOI":"10.1002\/mds.22418","type":"journal-article","created":{"date-parts":[[2009,1,2]],"date-time":"2009-01-02T03:07:38Z","timestamp":1230865658000},"page":"437-440","source":"Crossref","is-referenced-by-count":39,"title":["Zonisamide for essential tremor: An evaluator\u2010blinded study"],"prefix":"10.1002","volume":"24","author":[{"given":"Adrian","family":"Handforth","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredricka C.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail A.","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeba","family":"Vanek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,2,23]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2005.11.004"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2004.09.004"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00029679-199517060-00001"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20147"},{"key":"e_1_2_6_6_2","first-page":"271","volume-title":"Parkinson's disease and movement disorders","author":"Fahn SE","year":"1993"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870110306"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21412"},{"key":"e_1_2_6_9_2","first-page":"139","article-title":"Zonisamide in refractory essential tremor","volume":"46","author":"Bermejo PE","year":"2008","journal-title":"Rev Neurol"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21282"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/WNF.0b013e318074dd4f"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.22418","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.22418","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T13:18:25Z","timestamp":1760966305000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.22418"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,2,15]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,2,15]]}},"alternative-id":["10.1002\/mds.22418"],"URL":"https:\/\/doi.org\/10.1002\/mds.22418","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,2,15]]}}}